Drugs / SRA-444
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00499200 | Oct 2007 → Jun 2008 | Alzheimer disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00452504 | Feb → Jun 2007 | Alzheimer disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SRA-444 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00452504 ↗ |
| Route | Oral | “Administered Orally” NCT00452504 ↗ |